Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease
Circulation - United States
doi 10.1161/01.cir.0000069272.06194.91
Full Text
Open PDFAbstract
Available in full text
Date
April 22, 2003
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)